Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients

Rafat, Cédric; Vimont, Sophie; Ancel, Pierre‐Yves; Xu‐Dubois, Yi‐Chun; Laurent, Michel; Ouali, Nacéra; Michel, Denis; Vandewalle, Alain; Rondeau, Éric; Hertig, Alexandre

doi:10.1111/j.1399-3062.2011.00602.x

Cited by 22 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated that ofloxacin was independently associated with a reduction in the incidence of urinary tract infections [odds ratio (OR), 0.31; p = 0.02] and acute pyelonephritis (OR, 0.21; p = 0.045). The therapeutic effect of ofloxacin prophylaxis was maintained for the 1 st year post‐transplantation [31]. However, concerns regarding fluoroquinolone therapy remain.…”

Section: Discussionmentioning

confidence: 99%

Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta‐analysis

Song

Rao

Qiu

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Previous studies regarding the prevention of BK viremia following renal transplantation with fluoroquinolone have yielded conflicting results. The purpose of this systematic review was to examine the evidence regarding the efficacy of fluoroquinolone in preventing BK polyomavirus infection following renal transplantation. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for research articles published prior to January 2015 using keywords such as "fluoroquinolone," "BK viremia," and "renal transplantation." We extracted all types of study published in English. The primary outcome was BK viremia and viruria at 1 year post-transplantation. Secondary outcomes were BK virus-associated nephropathy (BKVN), graft failure, and fluoroquinolone-resistant infection. We identified eight trials, including a total of 1477 participants with a mean duration of fluoroquinolone prophylaxis of >1 month. At 1 year, fluoroquinolone prophylaxis was not associated with a decreased incidence of BK viremia [risk ratio (RR), 0.84; 95% confidence interval (95% CI), 0.58-1.20). No significant differences in BKVN (RR, 0.88; 95% CI, 0.37-2.11), risk of graft failure due to BKVN (RR, 0.68; 95% CI, 0.29-1.59), or fluoroquinolone-resistant infection (RR, 1.08; 95% CI, 0.64-1.83) were observed between the fluoroquinolone prophylaxis and control groups. The results of this study suggest that fluoroquinolone is ineffective in preventing BK polyomavirus infection following renal transplantation.

show abstract

Section: Discussionmentioning

confidence: 99%

Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta‐analysis

Song

Rao

Qiu

et al. 2016

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…In patients receiving trimethoprim‐sulfamethoxazole prophylaxis, 62% of urinary tract infections have been reported as caused by trimethoprim‐sulfamethoxazole‐resistant organisms . Use of fluroquinolones as prophylaxis for renal transplant recipients has been linked to surges in fluoroquinolone‐resistant Pseudomonas aeruginosa . Frequent use of antibiotics for treatment of asymptomatic bacteriuria also has been associated with antimicrobial resistance.…”

Section: Microbiology (Figure )mentioning

confidence: 99%

Urinary Tract Infections in Solid Organ Transplantation

Parasuraman

Julian

2013

American Journal of Transplantation

149

103

View full text Add to dashboard Cite

“…Ofloxacin is used in the treatment of several infectious diseases, such as typhoid fever, meningococcal infection, and recently, multibacillary leprosy [4][5][6]. The use of ofloxacin for urinary tract infection treatment has increased in the past decade because this antibiotic has excellent efficacy and increases resistance to older agents, such as trimethoprim and sulfamethoxazole [7]. Some studies have reported that ofloxacin could efficiently inhibit the growth of various tumor cells via induced apoptosis [8,9].…”

Section: Introductionmentioning

confidence: 98%

Synthesis, characterization and DNA-binding properties of Ru(II) complexes coordinated by ofloxacin as potential antitumor agents

Wang

Zeng

et al. 2015

Journal of Coordination Chemistry

View full text Add to dashboard Cite

Three Ru complexes coordinated by oxfloxacin, [Ru(L) 2 (OFX)]Cl·2H 2 O (L = bpy, 1; dmbpy, 2; phen, 3; and OFX = ofloxacin), were synthesized and characterized. These complexes can inhibit the growth of cervical cancer HeLa cells efficiently. Furthermore, these three complexes exhibited excellent binding affinities with DNA, as confirmed by spectroscopy methods and viscosity experiments. Therefore, the synthesized Ru(II) complexes have excellent DNA-binding abilities with potential applications in cancer chemotherapy.

show abstract

Ofloxacin: new applications for the prevention of urinary tract infections in renal graft recipients

Abstract: Our unintentional extension of prophylactic antibiotherapy with OFLO gave rise to a dramatic decrease in the 1-year incidence of UTI and APN in kidney recipients. Emergence of resistant strains is, however, a major concern.

Cited by 22 publications

References 33 publications

Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta‐analysis

Fluoroquinolone prophylaxis in preventing BK polyomavirus infection after renal transplant: A systematic review and meta‐analysis

Urinary Tract Infections in Solid Organ Transplantation

Synthesis, characterization and DNA-binding properties of Ru(II) complexes coordinated by ofloxacin as potential antitumor agents

Contact Info

Product

Resources

About